
    
      Screening was up to 24 days. Treatment period was continued until DP, unacceptable toxicity,
      or participant's refusal. Follow up period was continued until death, participant's refusal,
      or end of study, whichever came first.

      This trial was conducted in Japan, where the International Nonproprietary Name (INN)
      designation for the study molecule is "aflibercept" and this term is therefore used
      throughout the synopsis. In the US, the US proper name is "ziv-aflibercept".
    
  